128 related articles for article (PubMed ID: 26183402)
1. Evidence of continued injecting drug use after attaining sustained treatment-induced clearance of the hepatitis C virus: Implications for reinfection.
Valerio H; Goldberg DJ; Lewsey J; Weir A; Allen S; Aspinall EJ; Barclay ST; Bramley P; Dillon JF; Fox R; Fraser A; Hayes PC; Innes H; Kennedy N; Mills PR; Stanley AJ; Hutchinson SJ
Drug Alcohol Depend; 2015 Sep; 154():125-31. PubMed ID: 26183402
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs.
Weir A; McLeod A; Innes H; Valerio H; Aspinall EJ; Goldberg DJ; Barclay ST; Dillon JF; Fox R; Fraser A; Hayes PC; Kennedy N; Mills PR; Stanley AJ; Aitken C; Gunson R; Templeton K; Hunt A; McIntyre P; Hutchinson SJ
Drug Alcohol Depend; 2016 Aug; 165():53-60. PubMed ID: 27268294
[TBL] [Abstract][Full Text] [Related]
3. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ
J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387
[TBL] [Abstract][Full Text] [Related]
4. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.
Islam N; Krajden M; Shoveller J; Gustafson P; Gilbert M; Buxton JA; Wong J; Tyndall MW; Janjua NZ;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):200-210. PubMed ID: 28404135
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh.
Rahman M; Janjua NZ; Shafiq TKI; Chowdhury EI; Sarker MS; Khan SI; Reza M; Faruque MO; Kabir A; Anis AH; Azim T
Int J Drug Policy; 2019 Dec; 74():69-75. PubMed ID: 31542689
[TBL] [Abstract][Full Text] [Related]
6. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.
Mazhnaya A; Meteliuk A; Barnard T; Zelenev A; Filippovych S; Altice FL
Int J Drug Policy; 2017 Sep; 47():187-195. PubMed ID: 28811159
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
[TBL] [Abstract][Full Text] [Related]
8. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis.
Aspinall EJ; Corson S; Doyle JS; Grebely J; Hutchinson SJ; Dore GJ; Goldberg DJ; Hellard ME
Clin Infect Dis; 2013 Aug; 57 Suppl 2():S80-9. PubMed ID: 23884071
[TBL] [Abstract][Full Text] [Related]
9. Reinfection with hepatitis C virus following sustained virological response in injection drug users.
Grebely J; Knight E; Ngai T; Genoway KA; Raffa JD; Storms M; Gallagher L; Krajden M; Dore GJ; Duncan F; Conway B
J Gastroenterol Hepatol; 2010 Jul; 25(7):1281-4. PubMed ID: 20594256
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland.
Caven M; Baiano CX; Robinson EM; Stephens B; Macpherson I; Dillon JF
J Viral Hepat; 2021 Dec; 28(12):1744-1750. PubMed ID: 34525228
[TBL] [Abstract][Full Text] [Related]
11. Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors' Health Network.
Morris L; Smirnov A; Kvassay A; Leslie E; Kavanagh R; Alexander N; Davey G; Williams O; Gilks C; Najman J
Int J Drug Policy; 2017 Sep; 47():216-220. PubMed ID: 28666635
[TBL] [Abstract][Full Text] [Related]
12. Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.
Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J;
Int J Drug Policy; 2017 Sep; 47():230-238. PubMed ID: 28633998
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.
Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ;
Int J Drug Policy; 2017 Sep; 47():177-186. PubMed ID: 28624134
[TBL] [Abstract][Full Text] [Related]
14. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units.
Valencia J; Alvaro-Meca A; Troya J; Cuevas G; Gutiérrez J; Morro A; Alvarez J; Pulido L; Cañamares I; Escobar I; Moreno S; Ryan P
Int J Drug Policy; 2019 Oct; 72():181-188. PubMed ID: 31253391
[TBL] [Abstract][Full Text] [Related]
15. Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs.
Latham NH; Doyle JS; Palmer AY; Vanhommerig JW; Agius P; Goutzamanis S; Li Z; Pedrana A; Gottfredsson M; Bouscaillou J; Luhmann N; Mazhnaya A; Altice FL; Saeed S; Klein M; Falade-Nwulia OO; Aspinall E; Hutchinson S; Hellard ME; Sacks-Davis R
Liver Int; 2019 Dec; 39(12):2244-2260. PubMed ID: 31125496
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus reinfection following treatment among people who use drugs.
Grady BP; Schinkel J; Thomas XV; Dalgard O
Clin Infect Dis; 2013 Aug; 57 Suppl 2():S105-10. PubMed ID: 23884057
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C.
Pineda JA; Núñez-Torres R; Téllez F; Mancebo M; García F; Merchante N; Pérez-Pérez M; Neukam K; Macías J; Real LM;
J Infect; 2015 Nov; 71(5):571-7. PubMed ID: 26212868
[TBL] [Abstract][Full Text] [Related]
18. Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland.
Allen EJ; Palmateer NE; Hutchinson SJ; Cameron S; Goldberg DJ; Taylor A
Int J Drug Policy; 2012 Sep; 23(5):346-52. PubMed ID: 22940142
[TBL] [Abstract][Full Text] [Related]
19. Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection.
Artenie AA; Zang G; Daniel M; Fortier E; Jutras-Aswad D; Puzhko S; Bruneau J
Int J Drug Policy; 2017 Sep; 47():239-243. PubMed ID: 28587944
[TBL] [Abstract][Full Text] [Related]
20. Cross-border injection drug use and HIV and hepatitis C virus seropositivity among people who inject drugs in San Diego, California.
Horyniak D; Wagner KD; Armenta RF; Cuevas-Mota J; Hendrickson E; Garfein RS
Int J Drug Policy; 2017 Sep; 47():9-17. PubMed ID: 28683432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
